Update on medication abortion

被引：12

作者：

Beal, Margaret W. ^{[1
]}

机构：

[1] Yale Univ, Sch Nursing, New Haven, CT 06536 USA

来源：

JOURNAL OF MIDWIFERY & WOMENS HEALTH | 2007年 / 52卷 / 01期

关键词：

abortion; abortion access; Clostridium sordellii; induced abortion; legal induced abortion-related mortality; mifepristone; misoprostol; VAGINAL MISOPROSTOL; CONTROLLED-TRIAL; UNITED-STATES; MIFEPRISTONE; REGIMEN; WOMEN;

D O I：

10.1016/j.jmwh.2006.10.006

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

This article provides an overview of medication abortion in the United States 6 years after the approval of rnifepristone (RU486; Mifeprex; Danco Laboratories, LLC, New York, NY) by the US Food and Drug Administration (FDA). The adoption of mifepristone is considered in the context of epidemiologic data on abortion, abortion access, and the safety of abortion. The risks of medication and aspiration abortion are discussed in the context of abortion-related mortality, recent experience with obstetric and gynecologic infection with Clostridium sordellii, and the limits of scientific knowledge on the incidence of this infection in women. Innovative protocols studied since FDA approval of mifepristone are presented, and implications for clinical practice are discussed.

引用

页码：23 / 30

页数：8

共 41 条

[1]

*A GUTTM I, 2003, TRENDS AB US 1973 20

[2]

*A GUTTMACHER I, 2005, OV AB US

[3] The clinical spectrum of Clostridium sordellii bacteraemia:: two case reports and a review of the literature [J].